FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2324486956> ?p ?o ?g. }

• W2324486956 endingPage "ix50" @default.
• W2324486956 startingPage "ix50" @default.
• W2324486956 abstract "Background: Lapatinib (LAP), a tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR) 1/2, is active in HER2-positive metastatic breast cancer (MBC) that has progressed after trastuzumab (Tmab)-based therapy. Besides HER2, an optimal surrogate predictive biological marker has not been established for LAP efficacy. In this retrospective study, we searched for other clinical predicative makers except HER2 for LAP based treatment. Patients and Methods: Between June 2009 and November 2012, 66 HER2-MBC patients were treated with LAP and capecitabine (CAP) at our single institution. At a median follow-up of 13 months, mean age was 56.8 ( ± 9.8) years and 40 of 66 patients had received prior adjuvant chemotherapy including 17 Tmab containing regimen. Visceral metastases were identified in 44, bone metastases in 32, and brain metastases in 15. The median number of chemotherapeutic lines for metastatic disease before LAP treatment was 2 (range: 0-8), and 57 of 66 patients had received prior Tmab containing regimen with 33 vinorelbine, 32 taxanes, 29 CAP, and 12 endocrine therapies. We evaluated a correlation between the incidence of any adverse events (AEs) or basal characteristics factors and clinical outcome of 66 patients after Tmab progression. Results: The median time to progression free survival (PFS) was 259 days in the LAP-CAP combination in Tmab-refractory 66 patients. We compared 18 patients with longer PFS (LPFS) who had more than 12-month to 22 shorter PFS (SPFS) who had less than 6-month. LPFS had more frequent incidence of diarrhea (p < 0.035), hand-foot skin reaction (HFSR) (p < 0.016), and skin rash (p < 0.024) than SPFS. We reevaluated the correlation of these 3 AEs and outcome in all 66 patients, HFSR and Diarrhea were statistically significant favorable factors (p = 0.0004 and 0.0275) in Log rank analysis. Skin rash had tendency of predictive value of efficacy (p = 0.007 in generalized Wilcoxon). Furthermore, median PFS of patients who had all 3 AEs (n = 19) were 365 days, while 84 days (n = 6) who had not (p= 0. 18 × 10-3). We did not find any other clinical predictive factors except 3 AEs. Conclusions: EGFR inhibitor related toxicities might be alternative predicative markers for LAP in HER2-MBC patients." @default.
• W2324486956 created "2016-06-24" @default.
• W2324486956 creator A5021782707 @default.
• W2324486956 creator A5038169777 @default.
• W2324486956 creator A5052440202 @default.
• W2324486956 creator A5081696693 @default.
• W2324486956 creator A5084042251 @default.
• W2324486956 date "2013-11-01" @default.
• W2324486956 modified "2023-09-27" @default.
• W2324486956 title "Toxicities Can Be a Surrogate Predictive Marker for Lapatinib Efficacy in Patients with HER2 Positive Breast Cancer" @default.
• W2324486956 doi "https://doi.org/10.1093/annonc/mdt459.84" @default.
• W2324486956 hasPublicationYear "2013" @default.
• W2324486956 type Work @default.
• W2324486956 sameAs 2324486956 @default.
• W2324486956 citedByCount "0" @default.
• W2324486956 crossrefType "journal-article" @default.
• W2324486956 hasAuthorship W2324486956A5021782707 @default.
• W2324486956 hasAuthorship W2324486956A5038169777 @default.
• W2324486956 hasAuthorship W2324486956A5052440202 @default.
• W2324486956 hasAuthorship W2324486956A5081696693 @default.
• W2324486956 hasAuthorship W2324486956A5084042251 @default.
• W2324486956 hasBestOaLocation W23244869561 @default.
• W2324486956 hasConcept C121608353 @default.
• W2324486956 hasConcept C126322002 @default.
• W2324486956 hasConcept C141071460 @default.
• W2324486956 hasConcept C141341695 @default.
• W2324486956 hasConcept C143998085 @default.
• W2324486956 hasConcept C2775930923 @default.
• W2324486956 hasConcept C2777329042 @default.
• W2324486956 hasConcept C2777909004 @default.
• W2324486956 hasConcept C2779786085 @default.
• W2324486956 hasConcept C2781413609 @default.
• W2324486956 hasConcept C526805850 @default.
• W2324486956 hasConcept C530470458 @default.
• W2324486956 hasConcept C71924100 @default.
• W2324486956 hasConcept C90924648 @default.
• W2324486956 hasConceptScore W2324486956C121608353 @default.
• W2324486956 hasConceptScore W2324486956C126322002 @default.
• W2324486956 hasConceptScore W2324486956C141071460 @default.
• W2324486956 hasConceptScore W2324486956C141341695 @default.
• W2324486956 hasConceptScore W2324486956C143998085 @default.
• W2324486956 hasConceptScore W2324486956C2775930923 @default.
• W2324486956 hasConceptScore W2324486956C2777329042 @default.
• W2324486956 hasConceptScore W2324486956C2777909004 @default.
• W2324486956 hasConceptScore W2324486956C2779786085 @default.
• W2324486956 hasConceptScore W2324486956C2781413609 @default.
• W2324486956 hasConceptScore W2324486956C526805850 @default.
• W2324486956 hasConceptScore W2324486956C530470458 @default.
• W2324486956 hasConceptScore W2324486956C71924100 @default.
• W2324486956 hasConceptScore W2324486956C90924648 @default.
• W2324486956 hasLocation W23244869561 @default.
• W2324486956 hasOpenAccess W2324486956 @default.
• W2324486956 hasPrimaryLocation W23244869561 @default.
• W2324486956 hasRelatedWork W2012784647 @default.
• W2324486956 hasRelatedWork W2070897543 @default.
• W2324486956 hasRelatedWork W2088304505 @default.
• W2324486956 hasRelatedWork W2268282207 @default.
• W2324486956 hasRelatedWork W2406422093 @default.
• W2324486956 hasRelatedWork W3083051559 @default.
• W2324486956 hasRelatedWork W4231666740 @default.
• W2324486956 hasRelatedWork W4245535203 @default.
• W2324486956 hasRelatedWork W4281734204 @default.
• W2324486956 hasRelatedWork W813798061 @default.
• W2324486956 hasVolume "24" @default.
• W2324486956 isParatext "false" @default.
• W2324486956 isRetracted "false" @default.
• W2324486956 magId "2324486956" @default.
• W2324486956 workType "article" @default.